Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 1 Date: 25 Aug 2024
Reviewer's report:
The trial is interesting, and based on research
I have some comments;
2.2 Study Selection  please add (((Advanced stage))) to gastric cancer, or gastroesophageal
junction cancer.
3.4Safety results: Please delete second paragraph.  Also, it is worth adding more information
about certain side effects which were specifically higher in Nivolumab group, if possible.
Discussion:
Please compare your study to the study of Oyenuga et al; 2022,
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e16060
And reflect more on how your trial added to the current research,
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 1 Date: 25 Aug 2024
Reviewer's report:
The trial is interesting, and based on research
I have some comments;
2.2 Study Selection  please add (((Advanced stage))) to gastric cancer, or gastroesophageal
junction cancer.
3.4Safety results: Please delete second paragraph.  Also, it is worth adding more information
about certain side effects which were specifically higher in Nivolumab group, if possible.
Discussion:
Please compare your study to the study of Oyenuga et al; 2022,
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e16060
And reflect more on how your trial added to the current research,
Please review this paper.
user
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 1 Date: 25 Aug 2024
Reviewer's report:
The trial is interesting, and based on research
I have some comments;
2.2 Study Selection  please add (((Advanced stage))) to gastric cancer, or gastroesophageal
junction cancer.
3.4Safety results: Please delete second paragraph.  Also, it is worth adding more information
about certain side effects which were specifically higher in Nivolumab group, if possible.
Discussion:
Please compare your study to the study of Oyenuga et al; 2022,
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e16060
And reflect more on how your trial added to the current research,
assistant